| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
skaDivision of Laboratories and Research, New York State Department of Health, Albany, N.Y. 12201 [M. B., J. G.], and Department of Chemistry, Rensselaer Polytechnic Institute, Troy, N.Y. 12181 [J. K. C.]
The efflux of methotrexate and methotrexate polyglutamates was examined with primary monolayer cultures of rat hepatocytes and also with monolayer cultures of a stable hepatocarcinoma cell line (H35 cells). In this study, the polyglutamates were considered as those species with two or more additional glutamate residues. When methotrexate polyglutamates were present in hepatocytes in excess of methotrexate, efflux led to a further increase in the intracellular proportion of polyglutamates and a selective loss of methotrexate. The same was observed when methotrexate was the predominant intracellular species at the onset of efflux. In both cases, there was as low liberation of intact methotrexate polyglutamates. These results demonstrate that both methotrexate and methotrexate polyglutamates can cross the cell membrane but that methotrexate does so much more rapidly, resulting in selective retention of methotrexate polyglutamate derivatives.
Similar studies were conducted with H35 cells. When methotrexate polyglutamates were the predominant intracellular species (85% of the total methotrexate), there was a slow release of methotrexate polyglutamates. This was accompanied by approximately two-fold more rapid release of methotrexate. The latter was derived from the methotrexate polyglutamate pool since, during the course of efflux (six hr), the intracellular methotrexate concentration was constant, and the polyglutamates gradually decreased. This demonstrates that intact methotrexate polyglutamates can leave the cells, but this is probably not as rapid in H35 cells as cleavage to methotrexate and subsequent efflux.
Examination of the initial rate of efflux of methotrexate polyglutamates and methotrexate under similar conditions in H35 cells demonstrates that the rate of methotrexate efflux is nearly 70 times more rapid than the rate of polyglutamate efflux. Similar studies in hepatocytes indicate not less than a 10-fold more rapid efflux of methotrexate. The rate of efflux of the polyglutamate was nearly the same in hepatocytes and H35 cells.
Measurements of cell permeability during efflux showed no change in trypan blue uptake with either cell type, indicating that the loss of methotrexate and its polyglutamate derivatives did not appear to be due to cell fragility. Hepatocytes and H35 cells that were made permeable (90% permeable by trypan blue uptake) by lysolecithin treatment lost approximately 85% of the total intracellular methotrexate including polyglutamates within 2 min. There was no retention of any of the methotrexate species, indicating that the selective retention of methotrexate polyglutamates in untreated cells was due to reduced permeability.
1 Recipient of NIH Grant CA25933 awarded by the National Cancer Institute, USPHS, Department of Health and Human Services, and Grant AG00207 from the Institute on Aging, USPHS, Department of Health and Human Services. To whom requests for reprints should be addressed.
2 Recipient of NIH Grant CA28097 awarded by the National Cancer Institute, USPHS, Department of Health and Human Services.
Received 12/23/80. Accepted 4/ 1/81.
This article has been cited by other articles:
|
|
 |
|
  J. J. McGuire, W. H. Haile, and C.-C. Yeh 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res., April 1, 2006; 66(7): 3836 - 3844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Cole, R. A. Drachtman, A. K. Smith, S. Cate, R. A. Larson, D. S. Hawkins, J. Holcenberg, K. Kelly, and B. A. Kamen Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia Clin. Cancer Res., November 15, 2005; 11(22): 8089 - 8096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K-J Sohn, F Smirnakis, D N Moskovitz, P Novakovic, Z Yates, M Lucock, R Croxford, and Y-I Kim Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate Gut, December 1, 2004; 53(12): 1825 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zeng, Z.-S. Chen, M. G. Belinsky, P. A. Rea, and G. D. Kruh Transport of Methotrexate (MTX) and Folates by Multidrug Resistance Protein (MRP) 3 and MRP1: Effect of Polyglutamylation on MTX Transport Cancer Res., October 1, 2001; 61(19): 7225 - 7232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Cole, B. A. Kamen, R. Gorlick, D. Banerjee, A. K. Smith, E. Magill, and J. R. Bertino Effects of Overexpression of {{gamma}}-Glutamyl Hydrolase on Methotrexate Metabolism and Resistance Cancer Res., June 1, 2001; 61(11): 4599 - 4604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sirotnak Enhancing Cytotoxic Sensitivity of Tumor Cells to Antifolates: Another Opportunity for Gene Therapy? J Natl Cancer Inst, July 21, 1999; 91(14): 1178 - 1179. [Full Text] [PDF]
|
|
|
|
|
|
M. Aghi, C. M. Kramm, and X. O. Breakefield Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo J Natl Cancer Inst, July 21, 1999; 91(14): 1233 - 1241. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
